Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents

Drug Resistance Updates

Volumn 3, Issue 2, 2000, Pages 83-88

  Meijer, Laurent ^a  

^a STATION BIOLOGIQUE   (France)

Author keywords

Alzheimer's disease; Anticancer agents; Antineurodegenerative agents; Antiparasitic agents; Antiviral agents; Apoptosis; Cell cycle; Cyclin dependent kinase; Protein kinase inhibitors

Indexed keywords

2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE; 2 BIS(2 HYDROXYETHYL)AMINO 9 ISOPROPYL 6 (4 METHOXYBENZYLAMINO)PURINE; ALSTERPAULLONE; BUTYROLACTONE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; HYMENIALDISINE; INDIRUBIN 3' MONOXIME; KENPAULLONE; OLOMOUCINE; PURVALANOL A; ROSCOVITINE; TOYOCAMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL DIVISION; CRYSTALLIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITOR COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHOBICITY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0034176490     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0129     Document Type: Article

References (45)

1. Morgan D. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 13:1997;261-291.
2. Vogt PK, Reed SI. Cyclin dependent kinase (CDK) inhibitors. Current topics in microbiology and immunology. Springer Verlag, 1998.
3. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999;287:821-828.
4. Meijer L, Jezequel A Ducommun B (Eds). Progress in cell cycle research, vol. 4. Plenum Press, New York: 2000.
5. Meyerson M, Enders GH, Wu CL, et al. A family of human cdc2-related protein kinases. EMBO J 1992;11:2909-2917.
6. Plowman GD, Sudarsanam S, Bingham J, Whyte D, Hunter T. The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms. Proc Natl Acad Sci USA 1999;96:13603-13610.
7. Mandelkow E. The tangled tale of tau. Nature. 402:1999;588-589.
8. Patrick GN, Zukerberg L, Nikolic M, De la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:615-622.
9. Bibb JA, Snyder GL, Nishi A, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons. Nature 1999;402:669-671.
10. Gil-Gomez G, Berns A, Brady HJM.A link between cell cycle and cell death: Bax and Bcl-2 modulate cdk2 activation during thymocyte apoptosis. EMBO J 1998;17:7209-7218.
11. Hakem A, Sasaki T, Kozieradzki I, Penninger JM. The cyclin-dependent kinase cdk2 regulates thymocyte apoptosis. J Exp Med 1999;6:957-967.
12. Zhou BB, Li H, Yuan J, Kirschner MW. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc Natl Acad Sci USA 1998;95:6785-6790.
13. Harvey KJ, Lukovic D, Ucker DS. Caspase-dependent cdk activity is a requisite effector of apoptotic death events. J Cell Sci 2000;148:59-72.
14. Guo M, Hay BA. Cell proliferation and apoptosis. Curr Opin Cell Biol 1999;11:745-752.
15. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends in Cell Biol. 6:1996;393-397.
16. Meijer L, Kim SH. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol 1997;283:113-128.
17. Garrett MD, Fattaey A. Cyclin-dependent kinase inhibition and cancer therapy. Curr Opin Genet & Dev 1999;9:104-111.
18. Gray N., Détivaud L., Doerig C., Meijer L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem. 1999;6, 859-876.
19. Meijer L., Leclerc S., Leost M. Properties and potential applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol & Ther. 82:1999;279-284.
20. Sielecki TM, Boylan JF, Benfield PA, Trainor GL. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J Med Chem 2000;43:1-18.
21. Vesely J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine derivatives. Eur J Biochem 1994;224:771-786.
22. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-536.
23. de Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim S-H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997;243:518-526.
24. Gray N, Wodicka L, Thunnissen AM, et al. Exploiting chemical libraries, structure, and genomics in the search for new kinase inhibitors. Science 1998;281:533-538.
25. Chang YT, Gray NG, Rosania GR, et al. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem & Biol 1999;6:361-375.
26. Brooks EE, Gray NS, Joly A, et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem 1997;272:29207-29211.
27. Park SG, Cheon JY, Lee YH, Park J-S, Lee KY, Lee CH, Lee SK. A specific inhibitor of cyclin-dependent protein kinases, CDC2 and CDK2. Mol Cell 1996;6:679-683.
28. Sedlacek HH, Czech J, Naik R, et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Internat J Oncol 1996;9:1143-1168.
29. Zimmermann, J. Pharmacologically active pyrimidine derivatives and processes for the preparation thereof. PCT Ciba-Geigy, 1995, WO 95/09853.
30. Hoessel R, Leclerc S, Endicott J, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol 1999;1, 60-67.
31. Schultz C, Link A, Leost M, et al. The paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem 1999;42:2909-2919.
32. Zaharevitz D, Gussio R, Leost M, et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res 1999;59:2566-2569.
33. Kitagawa M., Okabe T., Ogino H. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene. 8:1993;2425-2432.
34. Meijer L, Thunissen AMWH, White A, et al. Inhibition of cyclin-dependent kinases, GSK-3β and casein kinase 1 by hymenialdisine, a marine sponge constituent. Chem & Biol 2000;7:51-63.
35. suc1-coated microtitration plates. Anticancer Res. 11:1991;1581-1590.
36. Rosania GR, Merlie J, Gray NS, Chang YT, Schultz PG, Heald R.A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification usingXenopus egg extracts. Proc Natl Acad Sci USA. 1999;96:4797-4802.
37. Knockaert M, Gray NS, Damiens E, et al. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised ligants. Chem & Biol 2000, (in press).
38. Nurse P., Bissett Y. Gene required in G1 for commitment to cell cycle and in G2 for control of mitosis in fission yeast. Nature. 292:1981;558-560.
39. Lee MG, Nurse P. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 1987;237:31-35.
40. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cylin-dependent kinase inhibitor in patients with refractory neoplasms. Clin Oncol 1998;16:2986-2999.
41. Hooijberg JH, Broxterman HJ, Scheffer GL, et al. Potent interaction of flavopiridol with MRP1. Br J Cancer 1999;81:269-276.
42. Bresnahan WA, Boldogh I, Chi P, Thompson EA, Albrecht T. Inhibition of cellular cdk2 activity blocks human cytomegalovirus replication. Virology 1997;231,239-247.
43. Schang LM, Phillips J, Schaffer PA. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol 1998;72:5626-5637.
44. Ye M, Duus KM, Peng J, Price DH, Grose C. Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase. J Virol 1999;73:1320-1330.
45. Kappes B, Doerig CD, Graeser R (1999) An overview of Plasmodium protein kinases. Parasitology Today 15:449-454.